loader from loading.io

Dissolvable Stent to Treat Peripheral Artery Disease Below the Knee with Dr. Ethan Korngold Abbott

Empowered Patient Podcast

Release Date: 11/11/2024

Aligning Incentives and Leveraging Technology to Improve Clinical Trials for Sponsors and Participants with Meri Beckwith Lindus Health TRANSCRIPT show art Aligning Incentives and Leveraging Technology to Improve Clinical Trials for Sponsors and Participants with Meri Beckwith Lindus Health TRANSCRIPT

Empowered Patient Podcast

Meri Beckwith, Co-Founder of Lindus Health, aims to transform clinical trials by changing the CRO model to leverage technology to improve patient recruitment, retention, and the experience of the sponsors and trial participants. While the compensation model for contract research organizations is often not aligned with trial outcomes, Lindus ties compensation to hitting milestones and outcomes. They emphasize the need for more flexible trial design and a decentralized and hybrid approach to reduce participant burden and bring drugs to market sooner.   Meri explains, "This comes back to...

info_outline
Aligning Incentives and Leveraging Technology to Improve Clinical Trials for Sponsors and Participants with Meri Beckwith Lindus Health show art Aligning Incentives and Leveraging Technology to Improve Clinical Trials for Sponsors and Participants with Meri Beckwith Lindus Health

Empowered Patient Podcast

Meri Beckwith, Co-Founder of Lindus Health, aims to transform clinical trials by changing the CRO model to leverage technology to improve patient recruitment, retention, and the experience of the sponsors and trial participants. While the compensation model for contract research organizations is often not aligned with trial outcomes, Lindus ties compensation to hitting milestones and outcomes. They emphasize the need for more flexible trial design and a decentralized and hybrid approach to reduce participant burden and bring drugs to market sooner.   Meri explains, "This comes back to...

info_outline
AI-Powered Cancer Biomarker Digital Detection Informs and Accelerates Decisions of Pathologists and Oncologists with Greg Hamilton io9 TRANSCRIPT show art AI-Powered Cancer Biomarker Digital Detection Informs and Accelerates Decisions of Pathologists and Oncologists with Greg Hamilton io9 TRANSCRIPT

Empowered Patient Podcast

Greg explains, "For many of these cancers, determining the right cancer treatment is the difference between life and death. When we look at how we treat cancer today, what hasn’t changed is that there’ll be a biopsy. So, they take a piece of the tumor out and send that tumor to a pathologist. Pathologists will take that tumor and put it in a glass slide. They usually use what’s called H&E, they kind of stain it to read it better. But basically, a pathologist is looking under a microscope at the cells, and that’s how we diagnose cancer. That’s the formal way that we diagnose...

info_outline
AI-Powered Cancer Biomarker Digital Detection Informs and Accelerates Decisions of Pathologists and Oncologists with Greg Hamilton io9 show art AI-Powered Cancer Biomarker Digital Detection Informs and Accelerates Decisions of Pathologists and Oncologists with Greg Hamilton io9

Empowered Patient Podcast

Greg Hamilton, CEO of io9, aims to enable precision oncology treatments for patients globally.  The company has developed an AI-powered biomarker analysis platform called OncoGaze that can rapidly analyze digital pathology images to identify cancer biomarkers. This enables pathologists to efficiently and quickly digitize and analyze tumor samples and oncologists to start patients on the appropriate targeted therapy much faster.   Greg explains, "For many of these cancers, determining the right cancer treatment is the difference between life and death. When we look at how we treat...

info_outline
Leveraging Antibody Phage Display Library to Generate Unique Bispecific Antibodies for Solid Tumors with Dr. Jeng Her AP Biosciences TRANSCRIPT show art Leveraging Antibody Phage Display Library to Generate Unique Bispecific Antibodies for Solid Tumors with Dr. Jeng Her AP Biosciences TRANSCRIPT

Empowered Patient Podcast

Dr. Jeng Her, Founder and CEO of AP Biosciences, is developing T-Cube bispecific antibodies that can target cancer cells and engage T-cells to kill them more effectively and safely than existing treatments. The company is focused on treating hard-to-treat cancers such as HER2-positive breast cancer, lung cancer, head and neck cancer, and pancreatic cancer. The T-Cube bispecific antibodies use CD137 instead of CD3 to activate T-cells, which can lead to better efficacy and safety compared to other T-cell engager antibodies. Jeng explains, "So why not just take two, let's say, monospecific...

info_outline
Leveraging Antibody Phage Display Library to Generate Unique Bispecific Antibodies for Solid Tumors with Dr. Jeng Her AP Biosciences show art Leveraging Antibody Phage Display Library to Generate Unique Bispecific Antibodies for Solid Tumors with Dr. Jeng Her AP Biosciences

Empowered Patient Podcast

Dr. Jeng Her, Founder and CEO of AP Biosciences, is developing T-Cube bispecific antibodies that can target cancer cells and engage T-cells to kill them more effectively and safely than existing treatments. The company is focused on treating hard-to-treat cancers such as HER2-positive breast cancer, lung cancer, head and neck cancer, and pancreatic cancer. The T-Cube bispecific antibodies use CD137 instead of CD3 to activate T-cells, which can lead to better efficacy and safety compared to other T-cell engager antibodies. Jeng explains, "So why not just take two, let's say, monospecific...

info_outline
Increasing Focus of Medical Device Companies on Regulations and Compliance with Sonia Veluchamy Celegence TRANSCRIPT show art Increasing Focus of Medical Device Companies on Regulations and Compliance with Sonia Veluchamy Celegence TRANSCRIPT

Empowered Patient Podcast

Sonia Veluchamy, CEO and Co-founder of Celegence discusses the increasing regulatory requirements and complexities faced by the medical device industry. Celegence works with companies to streamline their regulatory data management processes and adopt advanced technology solutions to manage compliance efficiently. Medical device companies are often slower than pharmaceutical companies to recognize the need to invest in data governance and process optimization to maintain compliance and avoid fines, delays in product approval, and loss of market access. Sonia explains, "The awareness is there,...

info_outline
Increasing Focus of Medical Device Companies on Regulations and Compliance with Sonia Veluchamy Celegence show art Increasing Focus of Medical Device Companies on Regulations and Compliance with Sonia Veluchamy Celegence

Empowered Patient Podcast

Sonia Veluchamy, CEO and Co-founder of Celegence discusses the increasing regulatory requirements and complexities faced by the medical device industry. Celegence works with companies to streamline their regulatory data management processes and adopt advanced technology solutions to manage compliance efficiently. Medical device companies are often slower than pharmaceutical companies to recognize the need to invest in data governance and process optimization to maintain compliance and avoid fines, delays in product approval, and loss of market access. Sonia explains, "The awareness is there,...

info_outline
Dissolvable Stent to Treat Peripheral Artery Disease Below the Knee with Dr. Ethan Korngold Abbott TRANSCRIPT show art Dissolvable Stent to Treat Peripheral Artery Disease Below the Knee with Dr. Ethan Korngold Abbott TRANSCRIPT

Empowered Patient Podcast

Dr. Ethan Korngold is the chief medical officer and divisional vice president of medical affairs at Abbott’s vascular business, which has developed a dissolvable stent technology to treat peripheral artery disease. PAD disproportionately affects Black and Hispanic communities and is often overlooked because early symptoms can be mistaken for other conditions. The Esprit BTK stent can help open up the smaller arteries below the knee and improve blood flow to the legs and feet to treat PAD and prevent severe complications and amputations. Ethan explains, "So peripheral artery disease...

info_outline
Dissolvable Stent to Treat Peripheral Artery Disease Below the Knee with Dr. Ethan Korngold Abbott show art Dissolvable Stent to Treat Peripheral Artery Disease Below the Knee with Dr. Ethan Korngold Abbott

Empowered Patient Podcast

Dr. Ethan Korngold is the chief medical officer and divisional vice president of medical affairs at Abbott’s vascular business, which has developed a dissolvable stent technology to treat peripheral artery disease. PAD disproportionately affects Black and Hispanic communities and is often overlooked because early symptoms can be mistaken for other conditions. The Esprit BTK stent can help open up the smaller arteries below the knee and improve blood flow to the legs and feet to treat PAD and prevent severe complications and amputations. Ethan explains, "So peripheral artery disease...

info_outline
 
More Episodes

Dr. Ethan Korngold is the chief medical officer and divisional vice president of medical affairs at Abbott’s vascular business, which has developed a dissolvable stent technology to treat peripheral artery disease. PAD disproportionately affects Black and Hispanic communities and is often overlooked because early symptoms can be mistaken for other conditions. The Esprit BTK stent can help open up the smaller arteries below the knee and improve blood flow to the legs and feet to treat PAD and prevent severe complications and amputations.

Ethan explains, "So peripheral artery disease refers to blockages in the arteries to the legs. When those blockages build up, it’s because of cholesterol typically that builds up in the walls of the artery and causes limited blood flow. Initially, people can have cramping or soreness in their legs when they walk. That gets better with rest. As the blockages get worse, people can develop infections, ulcers, or non-healing wounds of their legs with what we call chronic limb-threatening ischemia. And ultimately, that can put people at risk for amputation."

"A lot of people aren’t aware of how common it is, and a lot of people aren’t attuned to the symptoms of it. People just sort of slow down. They do less and less, and they wind up being limited in their activities, and that really affects their health and their life, and ultimately, that can threaten their limbs. One of the things that Abbott is emphatic about is spreading awareness of the disease, trying to educate patients, trying to educate families, and trying to educate physicians so that people are more on guard for looking out for the signs and symptoms of the disease."

"We have been working at Abbott for many years on techniques to help open up these blockages in the arteries of the legs. They start at about the belly button and go all the way down to the toes. At the belly button, the iliac arteries are quite large. They are about a half an inch in diameter. And then, as they go down all the way to the toes, they get narrower and narrower so that they’re about a quarter of an inch to an eighth of an inch in diameter. There are a variety of different techniques to get through those blockages, such as using catheters, and wires balloons, and stents and scaffolds to help open up those arteries and change people’s lives. One of the biggest challenges in this space has been those smaller arteries below the knee."

#Abbott #AbbottVascular #PeripheralArteryDisease #PAD #DissolvableStentTechnology

abbott.com

PAD-info.com

Download the transcript here

Abbott